Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors

Inclusion Criteria

• •Histologically diagnosed malignant solid tumor, including tumors of the CNS, that has progressed despite standard therapy or for which no effective standard therapy is known
• •* Patients with brainstem glioma or intrinsic pontine glioma do not need biopsy proof of the diagnosis if imaging studies are consistent with the diagnosis
• •Measurable or nonmeasurable disease
• •No pleural effusion or ascites causing respiratory compromise (≥ grade 2 dyspnea)
• •ECOG performance status (PS) 0-2 for patients ≥ 16 years of age
• •Karnofsky PS ≥ 40% for patients \> 10 years of age
• •Lansky Play Scale ≥ 40% for patients ≤ 10 years of age
• •Peripheral absolute neutrophil count (ANC) ≥ 1,000/mm\^3
• •Platelet count ≥ 75,000/mm\^3 (transfusion independent)
• •Hemoglobin ≥ 8.5 g/dL (transfusion permitted)
• •Serum creatinine ≤ 1.5 times upper limit of normal (ULN)
• •Creatinine clearance OR radioisotope glomerular filtration rate \> 60mL/min
• •Total bilirubin \< 1.5 mg/dL
• •ALT and AST ≤ 2.5 times ULN (5 times ULN if liver involvement with primary tumor)
• •Ejection fraction ≥ 50% OR shortening fraction ≥ 28%
• •Life expectancy of \> 8 weeks
• •No radiological evidence of pulmonary fibrosis, interstitial pneumonia, or extensive and symptomatic interstitial fibrosis of the lung
• •* Room air oxygen saturation ≥ 90% at altitudes ≥ 5,000 feet OR ≥ 93% at altitudes \< 5,000 feet
• •* DLCO \> 50% of predicted (for patients who received prior bleomycin and are able to comply with pulmonary function testing)
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No history of allergic reactions attributed to compounds of similar chemical or biologic composition to platinum or oxaliplatin as well as other agents used in study treatment
• •No other serious or poorly controlled social circumstance, psychiatric illness, or medical condition including, but not limited to, the following: ongoing or active infection, uncontrolled seizure disorder, uncontrolled symptomatic congestive heart failure, or cardiac arrhythmia that could be exacerbated by or complicate compliance with study therapy
• •No HIV-positive patients
• •Recovered from prior therapy
• •* No persistent toxicities from previous therapies ≥ grade 2
• •* Stable grade 3 neurotoxicity is allowed in patients with CNS tumors only who have a baseline neurotoxicity due to primary tumor involvement or postoperative complications
• •At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)
• •At least 4 weeks since prior local radiotherapy (small port)
• •At least 6 months since prior craniospinal irradiation, irradiation to ≥ 50% of the pelvis, or other substantial bone marrow irradiation, including total body irradiation
• •No previous treatment with oxaliplatin
• •At least 14 days since prior biological therapy (including monoclonalantibody therapy)
• •At least 7 days since prior retinoids, sargramostim (GM-CSF), or filgrastim (G-CSF)
• •At least 14 days since prior pegfilgrastim
• •No concurrent pegfilgrastim or GM-CSF
• •Patients requiring steroids should be on stable or decreasing dose for ≥ 7 days prior to study entry, and must not be on more than 4 mg of dexamethasone (or equivalent) per day
• •At least 4 weeks since prior major surgical procedure
• •* Simple surgical procedures, including biopsy or central line placement or similar procedure, are allowed within 4 weeks of study entry if the patient has recovered to baseline
• •At least 3 months since prior autologous or allogeneic stem cell transplantation
• •* No concurrent immunosuppressive therapy
• •* No evidence of ongoing graft versus host disease (GVHD)
• •No concurrent use of other investigational agents
• •No other concurrent anticancer therapies or agents
• •No other concurrent chemotherapy, radiation therapy, or herbal medications or supplements